TRAX First Tracks Biotherapeutics
Company Analysis
Latest News
🔴 First Tracks Biotherapeutics is trading 4.81% down today as major U.S. indexes fell sharply
First Tracks Biotherapeutics is trading 4.81% down at $45.96, with no confirmed company-specific catalyst and broad market weakness the likeliest context. -...
🟢 First Tracks Biotherapeutics is trading 5% up today after positive ANB033 celiac-trial results
First Tracks Biotherapeutics is trading at $48.76, up 5.22%, after positive ANB033 celiac-trial results. - The company reported a narrower third-quarter net...
First Tracks Biotherapeutics third quarter 2026 loss narrowed while pro forma cash reached $343M
First Tracks Biotherapeutics reported a net loss of $31.4 million for the third quarter ended September 30, 2026, as a reduction in legacy program spending...
🟢 First Tracks Biotherapeutics is trading 5.6% up today amid a strong biotech session
First Tracks Biotherapeutics is trading at $45.92, up 5.61%, with the move coinciding with a strong biotech session. - XBI was up 2.18%; no confirmed...
🟢 First Tracks Biotherapeutics is trading 10% up amid biotech-sector momentum
First Tracks Biotherapeutics is trading 10.02% higher at $39.91 on October 20, 2026, amid biotech-sector momentum. - No new company-specific announcement...
🟢 First Tracks Biotherapeutics is trading 5.9% up on October 20 amid biotech-sector strength
First Tracks Biotherapeutics is trading at $38.43, up 5.93%, with biotech-sector strength the best-supported context; no fresh company-specific announcement...
🟢 First Tracks Biotherapeutics is trading 5.4% up today amid biotech-sector strength
First Tracks Biotherapeutics is trading at $36.32, up 5.40%, during live trading, with biotech-sector strength providing relevant support; no direct...
🔴 First Tracks Biotherapeutics is trading 5% down today amid a 2.06% biotech-sector drop
First Tracks Biotherapeutics is trading 5.05% down at $34.22, amid broader market weakness and the biotech sector’s 2.06% drop. - Shares closed up 5.60% on...
First Tracks Biotherapeutics Announces ~$200 Million Private Placement of Common Stock
First Tracks Biotherapeutics has entered into a securities purchase agreement with several third-party investors for a private placement expected to generate...
🟢 First Tracks Biotherapeutics is trading 5% up today amid XBI's 2.20% regular-session gain
First Tracks Biotherapeutics is trading 5.04% higher at $35.85, with biotech-sector strength providing broader context. - The XBI is up 2.20% during the...
🟢 First Tracks Biotherapeutics is trading 5.6% up
First Tracks Biotherapeutics is trading at $33.46, up 5.62%, with no confirmed catalyst identified for the gain. - No fresh company announcement dated October...
🔴 First Tracks Biotherapeutics is trading 5% down in pre-market
First Tracks Biotherapeutics is trading 5.05% lower at $30.08 in pre-market, with no fresh catalyst established. - No new company announcement dated October...
First Tracks Biotherapeutics Announces Positive Phase 1b Data for Celiac Disease Drug ANB033
First Tracks Biotherapeutics announced positive top-line results from the first cohort of its Phase 1b clinical trial for ANB033, an investigational treatment...
🔴 First Tracks Biotherapeutics is trading 5% down today as biotech sector falls
First Tracks Biotherapeutics is trading at $32.25, down 5.29%, with no clear company-specific cause identified and the biotech sector also lower. - It closed...
🟢 First Tracks Biotherapeutics Surges on Positive Phase 1b Celiac Trial Results
First Tracks Biotherapeutics is trading at $37.35, up +20.64%, after announcing positive top-line results from Cohort 1 of its Phase 1b trial of ANB033 in...
TRAX Surges 21% on Eve of Celiac Trial Results — But Can a 30-Patient Study Justify a Billion-Dollar Bet?
Shares of First Tracks Biotherapeutics rocketed 20.9% to $38.50 in pre-market trading as investors positioned ahead of the company's most important milestone...
🟢 First Tracks Biotherapeutics is trading 21% up in pre-market ahead of October 12 ANB033 trial data
First Tracks Biotherapeutics is trading at $38.50, up 20.88%, ahead of its scheduled October 12 release of top-line ANB033 trial data. - The update is...
🟢 First Tracks Biotherapeutics is trading 7.1% up on October 8, 2026
First Tracks Biotherapeutics is trading at $32.75, up 7.06%, during the October 8 session, with no clear company-specific catalyst identified. - The...
🟢 First Tracks Biotherapeutics is trading 14.4% up in pre-market
First Tracks Biotherapeutics is trading 14.4% higher at $35.00 before the October 8, 2026 open; the cause is unclear. - Its investor-relations release page...
🟢 First Tracks Biotherapeutics is trading 8% up in pre-market with no clear catalyst identified
First Tracks Biotherapeutics is trading at $34.00, up 8.31% in pre-market, with no company-specific cause identified. - Shares closed at $31.39 on October...